Target intelligence / Profile preview

Cutibacterium acnes 50S ribosomal subunit (C. acnes 50S subunit)

Target
C. acnes 50S subunit
Molecular classification
Ribonucleoprotein complex, Ribosome
01

Overview

The Cutibacterium acnes 50S ribosomal subunit is a fundamental component of the protein synthesis machinery in the Gram-positive bacterium C. acnes, which is a key factor in the development of acne vulgaris (StatPearls, 2023). This large subunit is composed of 23S and 5S ribosomal RNA (rRNA) and approximately 33 ribosomal proteins, providing the structural framework for the peptidyl transferase center where peptide bond formation occurs (UniProt, 2024). It is the primary molecular target for several major classes of antibiotics used in dermatology, including macrolides (e.g., erythromycin) and lincosamides (e.g., clindamycin), which bind to the 23S rRNA to obstruct the ribosomal exit tunnel or the peptidyl transferase site (PubMed, 2021). By halting the production of bacterial proteins, these treatments effectively reduce C. acnes colonization and the subsequent release of pro-inflammatory enzymes and chemotactic factors (NIH, 2022). However, the clinical utility of targeting this subunit is increasingly compromised by the emergence of resistant strains harboring specific point mutations in the 23S rRNA gene or methyltransferase enzymes (Journal of Clinical Medicine, 2020). As a result, the 50S subunit remains a focal point for the development of novel antimicrobial scaffolds that can overcome established resistance patterns in skin infections.

Other names
Propionibacterium acnes 50S ribosomal subunit50S ribosomal subunit (Cutibacterium acnes)Large ribosomal subunit of C. acnesBacterial ribosome 50S subunit in Cutibacterium acnes
02

Mechanism of action

Inhibition of bacterial protein synthesis by binding to the 50S ribosomal subunit, specifically blocking the peptidyl transferase center or the exit tunnel, thereby preventing peptide chain elongation (StatPearls, 2023; PubMed, 2021).

03

Biological functions

Protein synthesisTranslationPeptide bond formationPeptidyl transferase activity
04

Disease associations

Acne vulgarisInfectionInflammation
05

Safety considerations

Development of antimicrobial resistanceDisruption of the skin and systemic microbiome (NIH, 2022)Topical irritation, erythema, and dryness (StatPearls, 2023)
06

Interacting drugs

Clindamycin

5 more in the full profile.

07

Biomarkers

23S rRNA gene mutations (e.g., A2058G, A2059G) for resistance monitoring (PubMed, 2021)Presence of erm(X) or erm(50) methylase genes (Journal of Clinical Medicine, 2020)

Beyond the preview

Go deeper on Cutibacterium acnes 50S ribosomal subunit (C. acnes 50S subunit).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cutibacterium acnes 50S ribosomal subunit (C. acnes 50S subunit).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call